SETDB1 promotes the expression of IGFBP4 (insulin like growth factor binding protein 4), LRP8 (LDL receptor related protein 8), and FZD1 (frizzled class receptor 1), but inhibits APOE (Apolipoprotein E) expression, thereby activating WNT-β-catenin pathway and suppressing P53 expression to enhance NSCLC growth in vitro and in vivo [90]. Here, FZD1 is linked to non-small cell lung carcinoma.